A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas (NCT05685173)
A Phase 1 Study to Assess Safety and Tolerability of REGN5837, an Anti-CD22 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Odronextamab, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With Aggressive B-Cell Non-Hodgkin Lymphomas (ATHENA-1)
🩺 Plain-English Summary (8th-Grade Level)
This study is researching an experimental drug called REGN5837 in combination with another drug, odronextamab (called "study drug\[s\]"), in patients with relapsed or refractory aggressive B-cell Non-Hodgkin Lymphomas (B-NHLs). The study has 2 parts. The aim of the first part (dose escalation) is to find a safe dose of REGN5837 when given in combination with odronextamab. The goal of the second part (dose expansion) is to use the REGN5837 drug dose found in the first part to see how well REGN5837 in combination with odronextamab works. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (that could make the drugs less effective or could lead to side effects)
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- City of Hope — Duarte, California
- University of California Los Angeles (UCLA) Medical Center — Santa Monica, California
- Norton Cancer Institute — Louisville, Kentucky
- Massachusetts General Hospital — Boston, Massachusetts
- Harvard Medical School - Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
- NYU Langone Health Perlmutter Cancer Center — New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- UT Southwestern — Dallas, Texas
- CHU de Bordeaux — Talence, New Aquitaine
- Hopital Saint Louis — Paris,
- Gustave Roussy — Villejuif, Île-de-France Region
- Erasmus Medical Center Rotterdam — Rotterdam, South Holland
- Amsterdam University Medical Centre, location AMC — Amsterdam,
- Hospital Vall d'Hebron — Barcelona,
- University Hospital and Research Institute — Madrid,
- Royal Cornwall Hospitals NHS Trust, Royal Cornwall Hospital — Truro, Cornwall
- Southampton General Hospital — Southampton, Hampshire
- Western General Hospital — Edinburgh, Scotland
- The Christie NHS Foundation Trust — Manchester,
📞 Contact the Study Coordinator
Phone: (844) 734-6643
Email: clinicaltrials@regeneron.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All B-cell Non-Hodgkins Lymphoma (B-NHL) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.